Trials / Completed
CompletedNCT00790790
A Study in the Treatment of Osteoarthritis Knee Pain
A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 147 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To gather data on whether a new drug for osteoarthritis knee pain will be safe and have an effect on pain levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | LY545694 placebo BID po for 5 weeks |
| DRUG | LY545694 49 mg | LY545694 49 mg BID po for 5 weeks. |
| DRUG | LY545694 105 mg | LY545694 105 mg BID po for 5 weeks. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-11-14
- Last updated
- 2012-04-17
- Results posted
- 2011-10-05
Locations
10 sites across 3 countries: United States, Puerto Rico, Romania
Source: ClinicalTrials.gov record NCT00790790. Inclusion in this directory is not an endorsement.